COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections

Background: To determine the effect of disease-modifying therapies (DMT) on humoral postvaccine seroconversion, long-term humoral response, and breakthrough COVID-19 infections in persons with multiple sclerosis (PwMS) and other neuroinflammatory disorders. Methods: A total of 757 PwMS and other neu...

Full description

Bibliographic Details
Published in:	Vaccines
Main Authors:	Dejan Jakimovski, Karen Zakalik, Samreen Awan, Katelyn S. Kavak, Penny Pennington, David Hojnacki, Channa Kolb, Alexis A. Lizarraga, Svetlana P. Eckert, Rosila Sarrosa, Kamath Vineetha, Keith Edwards, Bianca Weinstock-Guttman
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Subjects:	COVID-19 SARS-CoV-2 vaccination BNT162b2 mRNA-1273 Ad26.COV2.S breakthrough infection
Online Access:	https://www.mdpi.com/2076-393X/10/5/695

Similar Items

Is a single COVID-19 vaccine dose enough in convalescents ?
by: Daniele Focosi, et al.
Published: (2021-09-01)

Durability of Protection Post–Primary COVID-19 Vaccination in the United States
by: Amanda Zheutlin, et al.
Published: (2022-09-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

IMUNOGENICIDADE DE UM PRIMEIRO REFORÇO COM BNT162B2 OU MRNA-1273 DE DOSE COMPLETA: UM ESTUDO RANDOMIZADO EM ADULTOS ≥75 ANOS (EU-COVAT-1) DO CONSÓRCIO VACCELERATE
by: Jon Salmanton-Garcia, et al.
Published: (2023-10-01)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
by: Nigam H. Padhiar, et al.
Published: (2022-05-01)

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
by: Frédéric Baron, et al.
Published: (2022-03-01)

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01)

Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01)

The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines
by: Monika Skorupa, et al.
Published: (2022-03-01)

Safety and efficacy of RNA vaccines: State of the art
by: A. V. Blagov, et al.
Published: (2021-11-01)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
by: Farah M. Shurrab, et al.
Published: (2022-01-01)

Vaccine‐induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?
by: Julien Favresse, et al.
Published: (2024-08-01)

Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals
by: Susan L. Uprichard, et al.
Published: (2022-02-01)

Kinetics of SARS-CoV-2 Spike Antibodies after the Second and Third Dose of the BNT162b2 COVID-19 Vaccine and Association with Epidemiological Characteristics and Breakthrough Infection in a Cohort Study of Healthcare Workers
by: Elizabeth-Barbara Tatsi, et al.
Published: (2023-08-01)

SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but Do Not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses
by: Weiyi Tang, et al.
Published: (2025-03-01)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
by: Daniele Focosi, et al.
Published: (2022-01-01)

COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated
by: Anke Hüls, et al.
Published: (2022-03-01)

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination
by: Kevin D. Dieckhaus, et al.
Published: (2023-02-01)

Influence of the Single Nucleotide Polymorphisms rs12252 and rs34481144 in <i>IFITM3</i> on the Antibody Response after Vaccination against COVID-19
by: Ieva Čiučiulkaitė, et al.
Published: (2023-07-01)

SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review
by: Caterina Ledda, et al.
Published: (2022-01-01)

Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2
by: Michinobu Yoshimura, et al.
Published: (2024-01-01)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
by: Catherine E. Raptis, et al.
Published: (2022-10-01)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
by: Toshio Naito, et al.
Published: (2022-01-01)

Antibodies against Receptor Binding Domain of SARS-CoV-2 spike protein induced by BNT162b2 vaccine: results from a pragmatic, real-life study
by: Marcello Mariani, et al.
Published: (2021-10-01)

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant
by: Valentin Letailleur, et al.
Published: (2024-12-01)

Risk of herpes zoster following mRNA COVID-19 vaccine administration
by: Ana Florea, et al.
Published: (2023-12-01)

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
by: Daniele Focosi, et al.
Published: (2022-11-01)

Humoral and Memory B Cell Responses Following SARS-CoV-2 Infection and mRNA Vaccination
by: Martina Bozhkova, et al.
Published: (2025-07-01)

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
by: Julia M. Neuhann, et al.
Published: (2022-10-01)

Neurovascular Adverse Effects of Sars-Cov-2 Vaccination
by: Panos LD, et al.
Published: (2024-05-01)

Immune Imprinting, Non-Durable Hybrid Immunity, and Hybrid Immune Damping Following SARS-CoV-2 Primary Vaccination with BNT162b2 and Boosting with mRNA-1273
by: Alejo Erice, et al.
Published: (2025-03-01)

Clinical outcomes and risk factors for SARS-CoV-2 breakthrough cases following vaccination with BNT162b2, CoronaVac, or ChAdOx1-S: A retrospective cohort study in Malaysia
by: Hessa Tamim, et al.
Published: (2024-04-01)

Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern
by: Mandy Schwarze, et al.
Published: (2022-06-01)

A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
by: Marika Watanabe, et al.
Published: (2022-10-01)

Pityriasis rosea and pityriasis rosea-like eruption after anti-SARS-CoV-2 vaccination: a report of five cases and review of the literature
by: Stefano Veraldi, et al.
Published: (2022-07-01)

Anti-SARS-CoV-2 Revaccination Success in Kidney Transplant Recipients With No Initial Humoral Response Is Linked to Primary Vaccine Type
by: Julian Stumpf, et al.
Published: (2022-07-01)

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
by: Hagit Kopel, et al.
Published: (2024-09-01)

A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection
by: Zaeema Naveed, et al.
Published: (2024-03-01)

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
by: Soledad González, et al.
Published: (2022-09-01)

Long-Term Analyses of SARS-CoV-2 Humoral and T Cell Responses and Breakthrough SARS-CoV-2 Infections after Two Doses of BNT162b2 Followed by mRNA-1273 and Bivalent Omicron-Adapted BNT162b2 Vaccines: A Prospective Study over 2 Years in Non-Immunocompromised Individuals
by: Alejo Erice, et al.
Published: (2023-12-01)